Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC et al., (2015) 474 F.T.R. 256 (FC)
Linked as:
Extract
Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC et al., (2015) 474 F.T.R. 256 (FC)
No longer available (Autolink)
See the full content of this document
This document cites
- Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC et al., (2015) 473 F.T.R. 1 (FC)
- Sanofi-Synthelabo Canada Inc. et al. v. Apotex Inc. et al., (2008) 381 N.R. 125 (SCC)
- Fournier Pharma Inc. et al. v. Canada (Minister of Health) et al., (2012) 413 F.T.R. 277 (FC)
- Abbott Laboratories et al. v. Canada (Minister of Health) et al., 2009 FCA 94
- AstraZeneca Canada Inc. et al. v. Apotex Inc. et al., (2014) 457 F.T.R. 227 (FC)
